ReviewAmerican journal of cancer research2019

Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.

Jun-Cheng Xuhong et al.PubMed ↗Full text ↗

No numbers read from the abstract.